Bojun Wang
YOU?
Author Swipe
View article: IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash: preclinical and clinical responses
IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash: preclinical and clinical responses Open
View article: Supplementary Figure 7 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
Supplementary Figure 7 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
USP15 facilitates the stability of the SMYD3 protein by deubiquitination.
View article: Data from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
Data from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
Colorectal cancer creates a suppressive tumor immune microenvironment that leads to tumor progression and resistance to immune checkpoint inhibitor therapy. Ubiquitin-specific protease 15 (USP15) broadly regulates immune responses and immu…
View article: Supplementary Figure 6 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
Supplementary Figure 6 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
Validation of the relationship between USP15 and TP53/MDM2 expression in CRC cells and tumors.
View article: Supplementary Figure 1 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
Supplementary Figure 1 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
USP15 is upregulated and correlates with poor prognosis in CRC.
View article: Supplementary Table 2 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
Supplementary Table 2 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
Clinical information of Cohort 2 comprising 93 patients.
View article: Supplementary Figure 11 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
Supplementary Figure 11 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
Graphical abstract.
View article: Supplementary Table 3 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
Supplementary Table 3 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
CyTOF Antibodies Table.
View article: Supplementary Figure 2 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
Supplementary Figure 2 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
USP15 promotes tumor growth in CRC immunocompetent mice models.
View article: Supplementary Figure 8 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
Supplementary Figure 8 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
SMYD3 promotes CCL2 expression via trimethylation of H3K4 in CRC.
View article: Supplementary Figure 5 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
Supplementary Figure 5 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
MDSC is indispensable for remodeling USP15-induced suppressive TIME.
View article: Supplementary Figure 3 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
Supplementary Figure 3 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
USP15 induces high MDSC infiltration and low CD8+T cells infiltration in the CRC microenvironment.
View article: Supplementary Figure 10 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
Supplementary Figure 10 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
The effect of USP15 inhibitor on the proliferation of colorectal cancer cells.
View article: Supplementary Figure 4 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
Supplementary Figure 4 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
Immune cell composition and macrophage polarization in CT26-WT and CT26-Usp15 KO subcutaneous tumors.
View article: Supplementary Table 1 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
Supplementary Table 1 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
Clinical information of Cohort 1 comprising 78 patients.
View article: Supplementary Figure 9 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
Supplementary Figure 9 from USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
Blocking USP15 augments the anti-PD-1 therapy in CRC Models through MDSCs reprogramming.
View article: Evaluating the predictive performance of PIRO score against six clinical prediction scores for COVID-19 outcomes in the emergency department
Evaluating the predictive performance of PIRO score against six clinical prediction scores for COVID-19 outcomes in the emergency department Open
View article: USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment
USP15 Facilitates Colorectal Cancer Immune Evasion through SMYD3/CCL2-Dependent Myeloid-Derived Suppressor Cell Recruitment Open
Colorectal cancer creates a suppressive tumor immune microenvironment that leads to tumor progression and resistance to immune checkpoint inhibitor therapy. Ubiquitin-specific protease 15 (USP15) broadly regulates immune responses and immu…
View article: Supplementary WB raw data from Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer
Supplementary WB raw data from Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer Open
Supplementary WB raw data
View article: Figure S1-12 from Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer
Figure S1-12 from Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer Open
Supplementary Figure and Figure Legend
View article: Materials and Methods from Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer
Materials and Methods from Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer Open
Supplementary Materials and Methods
View article: Supplementary table 1 from Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer
Supplementary table 1 from Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer Open
Clinical and prognostic information of ARID1A proficient and ARID1A deficient colorectal cancer patients receiving immune checkpoint inhibitors, bevacizumab or cetuximab therapy
View article: Data from Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer
Data from Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer Open
AT-rich interactive domain-containing protein 1A (ARID1A), a core constituent of the switch/sucrose nonfermentable (SWI/SNF) complex, is mutated in approximately 10% of colorectal cancers. Whereas ARID1A deficiency corresponds to heightene…
View article: Supplementary Table 2 from Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer
Supplementary Table 2 from Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer Open
Metabolomics analysis data of CT26 WT and CT26 ARID1A-KO cells
View article: Raw metabolomics data from Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer
Raw metabolomics data from Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer Open
Supplementary raw metabolomics data
View article: Table S15 from Multiomics Reveals the Immunologic Features and the Immune Checkpoint Blockade Potential of Colorectal Medullary Carcinoma
Table S15 from Multiomics Reveals the Immunologic Features and the Immune Checkpoint Blockade Potential of Colorectal Medullary Carcinoma Open
Supplementary Table 15. KEGG results between MeC and nMeC
View article: Table S7 from Multiomics Reveals the Immunologic Features and the Immune Checkpoint Blockade Potential of Colorectal Medullary Carcinoma
Table S7 from Multiomics Reveals the Immunologic Features and the Immune Checkpoint Blockade Potential of Colorectal Medullary Carcinoma Open
Supplementary Table 7. Histologic types, group, TMB and MSI information about TCGA-COAD
View article: Table S16 from Multiomics Reveals the Immunologic Features and the Immune Checkpoint Blockade Potential of Colorectal Medullary Carcinoma
Table S16 from Multiomics Reveals the Immunologic Features and the Immune Checkpoint Blockade Potential of Colorectal Medullary Carcinoma Open
Supplementary Table 16. Immune landscape analysis between MeC and nMeC
View article: Table S5 from Multiomics Reveals the Immunologic Features and the Immune Checkpoint Blockade Potential of Colorectal Medullary Carcinoma
Table S5 from Multiomics Reveals the Immunologic Features and the Immune Checkpoint Blockade Potential of Colorectal Medullary Carcinoma Open
Supplementary Table 5. Group information for TCR-sequencing
View article: Table S2 from Multiomics Reveals the Immunologic Features and the Immune Checkpoint Blockade Potential of Colorectal Medullary Carcinoma
Table S2 from Multiomics Reveals the Immunologic Features and the Immune Checkpoint Blockade Potential of Colorectal Medullary Carcinoma Open
Supplementary Table 2. TMB and MSI information